Kratom is not chemically a classic opioid, but its active compounds act on the brain’s opioid receptors \u2014 which is why it produces opioid-like effects and opioid-like dependence.<\/p>\n
Kratom comes from the leaves of Mitragyna speciosa<\/em>, a tree native to Southeast Asia. Its two main active compounds, mitragynine and 7-hydroxymitragynine (7-OH), bind to the same mu-opioid receptors that prescription opioids target.<\/p>\n Federal agencies treat it as opioid-acting: the Drug Enforcement Administration<\/a> lists kratom as a drug of concern, and the National Institute on Drug Abuse<\/a> notes that its compounds activate the same brain receptors as other drugs with known addictive potential.<\/p>\n So the precise answer is: not an opioid by origin, but opioid-acting by mechanism. That distinction matters \u2014 because it is exactly why people underestimate it.<\/p>\n Kratom’s effects depend on dose: lower amounts tend to act like a stimulant, while higher amounts produce opioid-like sedation and pain relief.<\/p>\n This dual effect is well documented in the clinical literature. At low doses, people who use kratom report increased energy and alertness; at higher doses, they report sedation and pain relief closer to an opioid.<\/p>\n Mitragynine and 7-OH are partial agonists at the mu-opioid receptor, meaning they activate it but not as fully as a drug like morphine.<\/p>\n They are also described in research as G-protein-biased agonists<\/a> that do not strongly recruit a signaling protein called beta-arrestin-2.<\/p>\n That detail has a practical consequence. Beta-arrestin-2 signaling is linked to the respiratory depression<\/a> that makes classic opioid overdose so lethal, so leaf kratom tends to suppress breathing less than morphine or fentanyl. Lower risk is not the same as no risk \u2014 and concentrated products change that math, as the next section explains.<\/p>\n The dose-dependent effect is why kratom gets marketed for two opposite reasons \u2014 energy and focus on one hand, pain and anxiety relief on the other.<\/p>\n It is also why dependence can build quietly. Someone using kratom for daytime energy and again for evening pain may be dosing far more often than they realize.<\/p>\n On July 29, 2025, the FDA recommended that the DEA classify concentrated 7-OH products as Schedule I controlled substances \u2014 the most aggressive federal action<\/a> on kratom compounds since 2016.<\/p>\n FDA leadership has publicly described<\/a> concentrated 7-OH as a potent opioid and a major public-health concern.<\/p>\n As of mid-2026, the DEA had not finalized that scheduling, so concentrated 7-OH remains federally unscheduled even as several states \u2014 including Florida \u2014 have restricted it under their own laws. The recommendation targeted concentrated products specifically, not natural whole-leaf kratom.<\/p>\n The takeaway for anyone using these products: the legal status is unsettled, but the pharmacology is not. Concentrated 7-OH behaves like a potent opioid.<\/p>\n Yes \u2014 regular kratom use can lead to tolerance, physical dependence<\/a>, and a pattern of use that meets the clinical definition of a substance use disorder.<\/p>\n The Diagnostic and Statistical Manual of Mental Disorders<\/em> (DSM-5) has no kratom-specific diagnosis, so clinicians generally assess kratom use against opioid use disorder criteria. Dependence tends to build faster and harder with concentrated 7-OH than with leaf.<\/p>\n Dependence usually shows up gradually: needing more to get the same effect, dosing on a schedule to avoid feeling unwell, and finding it hard to stop despite wanting to.<\/p>\n Common signs include:<\/p>\n Many people who use kratom are trying to manage something else \u2014 chronic pain, anxiety, depression, or withdrawal from prescription opioids. That underlying reason matters, and it shapes what effective treatment looks like.<\/p>\n Beyond dependence, Mayo Clinic<\/a> notes that kratom has been linked to liver injury, seizures, and high blood pressure, and that unregulated products have been found contaminated with heavy metals and salmonella.<\/p>\n Kratom use during pregnancy has also been associated with newborn withdrawal. Because kratom is unregulated, potency and purity vary widely from product to product.<\/p>\n A quick gut check.<\/strong> If reading the signs above felt a little too familiar, that recognition is worth acting on \u2014 not panicking over. A conversation is free, and your insurance may cover more than you expect. Call Discover Recovery at 866.719.2173.<\/p>\n Kratom withdrawal resembles opioid withdrawal because of how it acts on mu-opioid receptors \u2014 generally milder than withdrawal from strong opioids like fentanyl, though concentrated 7-OH narrows that gap.<\/p>\n Withdrawal happens because the brain adapts to kratom’s presence. When it is suddenly removed, the body needs time to rebalance, and that adjustment produces symptoms.<\/p>\n Symptoms are a mix of physical and psychological, and they tend to come in waves:<\/p>\n Most people who stop after regular use follow a recognizable pattern, though duration varies with how much, how long, and what form was used.<\/p>\nHow Kratom Works in the Brain<\/strong><\/h2>\n
Mitragynine, 7-OH, and the mu-opioid receptor<\/strong><\/h3>\n
Why low doses stimulate and high doses sedate<\/strong><\/h3>\n
Where 7-OH regulation stands in 2026<\/strong><\/h3>\n
Is Kratom Addictive?<\/strong><\/h2>\n
Tolerance, dependence, and signs to recognize<\/strong><\/h3>\n
\n
Other health risks<\/strong><\/h3>\n
Kratom Withdrawal: Symptoms and Timeline<\/strong><\/h2>\n
Common withdrawal symptoms<\/strong><\/h3>\n
\n
The withdrawal timeline<\/strong><\/h3>\n
![\"Dr.](\"https:\/\/discover-recovery-1410e39.ingress-florina.ewp.live\/wp-content\/uploads\/2025\/03\/Kevin_Fischer1.jpg\")
<\/p>\n